Currently multiple clinical studies investigate the potential of PI3K/Akt pathway inhibitors to improve the outcome of chemotherapy and radiotherapy in cancer patients (phase 1 clinical studies involving BKM120 or BYL719 to radiosensitize cells)44, 45, 46. The gene discussed is AKT1; the disease is cancer.